Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6155947 | Translational Research | 2016 | 9 Pages |
Abstract
There is no Food and Drug Administration-approved treatment for acute respiratory distress syndrome (ARDS), in spite of the relatively large number of patients with the diagnosis. In this report, we provide an overview of preclinical studies and a description of completed and future clinical trials in humans with ARDS. Preclinical studies dealing with acute lung injury have suggested roles for complement and complement receptors, as well as the evolving role of histones, but details of these pathways are inadequately understood. Anti-inflammatory interventions have not been convincingly effective. Various cell growth factors are being considered for clinical study. Interventions to block complement activation or its products are under consideration. Stem cell therapies have shown efficacy in preclinical studies, which have motivated phase I/II trials in humans with ARDS.
Keywords
LPSAECARDSPMNsGM-CSFPAMPsDAMPsNETsTLRsAcute lung injurydanger-associated molecular patternspathogen-associated molecular patternsAliischemia-reperfusionBALFneutrophil extracellular trapsalveolar epithelial cellAcute respiratory distress syndromegranulocyte-macrophage colony-stimulating factorlipopolysaccharideBronchoalveolar lavage fluidToll-like receptors
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Theodore J. Standiford, Peter A. Ward,